DOI: 10.5683/sp3/dblsma
title: Search strategy for patient reported outcomes AND cancer immunotherapy
title: Replication Data for: "Development and evaluation of patient-reported outcomes (PROs) programs for patients treated with immune checkpoint inhibitors (ICIs): A scoping review"

description: The notes field contains the full MEDLINE (Ovid) search strategy for patient reported outcomes AND cancer immunotherapy. The file in this dataset contains the full Ovid MEDLINE, Ovid Embase, Ovid PsycInfo, and Ebsco CINAHL search strategies for patient reported outcomes AND cancer immunotherapy. An iterative process was used for the data collection of this scoping review, with an initial screening done of the Ovid Medline and Ovid Embase search results (search date March 10 2021), and a second screening done of updated Ovid Medline and Ovid Embase search results as well as searches translated into Ovid PsycInfo, and Ebsco CINAHL (search date December 17, 2021). Also included in the file are details pertaining to the grey literature search including search strategies used in Scopus and Proquest Global Theses and Dissertations.
description: (*Patient Outcome Assessment/ or *Health Status Indicators / or *"Quality of Life"/ or exp *"Surveys and Questionnaires"/ or exp *Treatment Outcome / or *Patient Reported Outcome Measures / or *Diagnostic Self Evaluation / or *Self Disclosure / or *Self-Assessment/ or Psychometrics / or exp Qualitative Research/ or (self-care or self-rating-anxiety-scale or Edmonton-symptom-assessment-system or close-person-questionnaire or distress-thermometer or Electronic-Self-Report-Cancer or ((self or patient*) adj (assess* or report* or evaluat* or disclos* or satisfaction or experience* or manag* or attitude* or concept or perception*)) or ((Electronic-Self-Report) ADJ2 (cancer))).tw,kf or (quality-of-life).ti) and (exp Immunotherapy/ or Antineoplastic Agents, Immunological/ or T-Lymphocytes, Cytotoxic / or Nivolumab/ or exp Immune Checkpoint Proteins / or Ipilimumab/ or avelumab/ or Adjuvants, Immunologic/ or Immunotherapy, Adoptive/ or Nivolumab/ or (immunotherap* or radioimmunotherap* or immunopotentiat* or immunostimul* or immunonutrition or immunoactivator* or immunoadjuvant* or donor-lymphocyte-infusion* or chimeric-antigen-receptor-therap* or antigen B7 H1 or antigen B7H1 or antigen CD274 or B7 H1 antigen or B7 H1 protein or B7 homolog 1 protein or B7H1 antigen or B7H1 protein or CD274 antigen* or PDCD1 ligand 1 or PDCD1LG1 protein or programmed cell death 1 ligand 1 or programmed death 1 ligand 1 protein or programmed death ligand 1 or program death 1 or protein B7 H1 or protein B7H1 or protein PDCD1LG1 or checkpoint-inhibitor* or checkpoint-blockade* or anti-PD1 or anti-PD-1 or anti-PDL1 or anti-PD-L1 or anti-CTLA4 or cytotoxic T-lymphocyte-associated protein 4 or nivolumab or opdivo or pembrolizumab or keytruda or durvalumab or imfinzi or cemiplimab or libtayo or ipilimumab or yervoy or avelumab or bavencio or ((immun* or BRM or response-modifier or CAR or cytol*) adj3 (therap* or intervention* or lymphocyte* or cell* or adjuvant*))).tw,kf.) and (exp Neoplasms/ or exp Carcinoma/ or Cancer Vaccines / or cancer palliative therapy/ or Cancer Survivors/ or (cancer* or tumo?r* or carcinoma* or adenocarcinoma* or neoplas* or oncolog* or metasta* or malignan* or choriocarcinoma* or sarcoma* or lymphoma* or melanoma* or myeloma*).tw,kf.)